Notice for belumosudil (Kadmon Oceania Pty Ltd)
Active ingredients
belumosudil
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
Treatment of patients 12 years and older with chronic Graft Versus Host Disease (GVHD) after failure of at least one prior line of systemic therapy
Therapeutic area
Oncology